Klea Pharmaceuticals begins its growth in the Middle East

Klea Pharmaceuticals, a subsidiary of KLEA HOLDING, announces its first order, marking the launch of its commercial operations in the Middle East. The order, placed by Alphamed in the United Arab Emirates, initiates the distribution of 57 licensed medications. This development follows the completion of the transfer of ownership of these products, enabling the company to compete in both public and private markets.

The company plans rapid expansion, targeting neighboring markets such as Bahrain and Qatar. Klea Pharmaceuticals anticipates revenues exceeding €2 million in 2026 and aims for €50 million by 2032.

To strengthen its strategy, Klea has appointed Imad Khalfi as Chief Commercial Officer and Abbas Deesawala as Chief Strategy Officer. These appointments aim to support strong and profitable growth in the MENA region.